Efficacy and safety of erythropoietin in a chronic model of inflammatory bowel disease

Detalhes bibliográficos
Autor(a) principal: Silva, Inês
Data de Publicação: 2022
Outros Autores: Estarreja, João, Pinto, Rui, Mateus, Vanessa
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.21/15129
Resumo: FCT_UIDB/05608/2020. FCT_UIDP/05608/2020.
id RCAP_6d0328de02c780a7c9cee6b802f9333f
oai_identifier_str oai:repositorio.ipl.pt:10400.21/15129
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Efficacy and safety of erythropoietin in a chronic model of inflammatory bowel diseaseAnti-inflammatory effectDrug repositioningErythropoietinExperimental colitisInflammatory bowel diseaseTNBS-induced colitisFCT_UIDB/05608/2020FCT_UIDP/05608/2020FCT_UIDB/05608/2020. FCT_UIDP/05608/2020.Background: Inflammatory Bowel Disease (IBD) is recognized as a group of chronic inflammatory disorders, localized in the gastrointestinal tract, which does not have a cure known. Indeed, the pharmacological approaches, commonly used, demonstrate significant toxicity, which highlights the need of investigating new possible treatments. Erythropoietin (EPO) is clinically used in anemic patients, with chronic renal insufficiency, due to its erythropoietic effect. However, it has also been described other non-erythropoietic effects, such as an anti-inflammatory role. There is already preclinical evidence about its anti-inflammatory effect in the IBD context, namely in an acute model of colitis in mice. Therefore, it is relevant to ascertain its anti-inflammatory effect in a chronic model, but mainly its hematopoietic side effect, during chronic treatment. Aim: This experiment aims to evaluate the efficacy and safety of EPO treatment in a chronic 2,4,6-Trinitrobenzenesulfonic acid (TNBS)-induced colitis model in rodents. Methods: The induction of chronic colitis consisted of five weekly intrarectal administrations of 1% TNBS, and then mice were treated daily with 500 IU/Kg or 1000 IU/Kg of EPO, through intraperitoneal injections, for 14 days. Results: EPO demonstrated a significant anti-inflammatory effect, translated by a significant reduction of the concentration of tumor necrosis factor-α, fecal calprotectin, and fecal hemoglobin. Moreover, it has also been demonstrated to be safe, considering the cardiovascular system, in terms of extraintestinal manifestations, namely at renal and hepatic functions. Conclusions: EPO demonstrated to be a promising pharmacological approach to be considered in the management of IBD, being an interesting target for drug repositioning.ElsevierRCIPLSilva, InêsEstarreja, JoãoPinto, RuiMateus, Vanessa2022-12-07T15:36:31Z2022-122022-12-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.21/15129engSilva IJ, Estarreja J, Pinto R, Mateus V. Efficacy and safety of erythropoietin in a chronic model of inflammatory bowel disease. Biomed Pharmacother. 2022;156:113944.10.1016/j.biopha.2022.113944info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-08-03T10:12:17Zoai:repositorio.ipl.pt:10400.21/15129Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:22:51.205633Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Efficacy and safety of erythropoietin in a chronic model of inflammatory bowel disease
title Efficacy and safety of erythropoietin in a chronic model of inflammatory bowel disease
spellingShingle Efficacy and safety of erythropoietin in a chronic model of inflammatory bowel disease
Silva, Inês
Anti-inflammatory effect
Drug repositioning
Erythropoietin
Experimental colitis
Inflammatory bowel disease
TNBS-induced colitis
FCT_UIDB/05608/2020
FCT_UIDP/05608/2020
title_short Efficacy and safety of erythropoietin in a chronic model of inflammatory bowel disease
title_full Efficacy and safety of erythropoietin in a chronic model of inflammatory bowel disease
title_fullStr Efficacy and safety of erythropoietin in a chronic model of inflammatory bowel disease
title_full_unstemmed Efficacy and safety of erythropoietin in a chronic model of inflammatory bowel disease
title_sort Efficacy and safety of erythropoietin in a chronic model of inflammatory bowel disease
author Silva, Inês
author_facet Silva, Inês
Estarreja, João
Pinto, Rui
Mateus, Vanessa
author_role author
author2 Estarreja, João
Pinto, Rui
Mateus, Vanessa
author2_role author
author
author
dc.contributor.none.fl_str_mv RCIPL
dc.contributor.author.fl_str_mv Silva, Inês
Estarreja, João
Pinto, Rui
Mateus, Vanessa
dc.subject.por.fl_str_mv Anti-inflammatory effect
Drug repositioning
Erythropoietin
Experimental colitis
Inflammatory bowel disease
TNBS-induced colitis
FCT_UIDB/05608/2020
FCT_UIDP/05608/2020
topic Anti-inflammatory effect
Drug repositioning
Erythropoietin
Experimental colitis
Inflammatory bowel disease
TNBS-induced colitis
FCT_UIDB/05608/2020
FCT_UIDP/05608/2020
description FCT_UIDB/05608/2020. FCT_UIDP/05608/2020.
publishDate 2022
dc.date.none.fl_str_mv 2022-12-07T15:36:31Z
2022-12
2022-12-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.21/15129
url http://hdl.handle.net/10400.21/15129
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Silva IJ, Estarreja J, Pinto R, Mateus V. Efficacy and safety of erythropoietin in a chronic model of inflammatory bowel disease. Biomed Pharmacother. 2022;156:113944.
10.1016/j.biopha.2022.113944
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133500582920192

Registros relacionados